Business Context and Reporting Period
This Form 8-K was filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on July 2, 2025. The filing reports a corporate action approved by stockholders on May 12, 2025, and effective July 7, 2025. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The company implemented a one-for-fifteen reverse stock split. Every fifteen shares of common stock issued and outstanding were combined into one share.
- Purpose: The amendment to the Certificate of Incorporation was approved primarily to meet the minimum bid price requirements of The Nasdaq Capital Market.
- Fractional Shares: No fractional shares will be issued. Entitlements of one-half or more of a fractional share are rounded up; those less than one-half are rounded down.
- Securities Adjustment: All outstanding options, warrants, and convertible securities were adjusted in accordance with their governing terms and rounded to the nearest whole share.
- Trading Details: The trading symbol remains "CYCC," but the company was assigned a new CUSIP number (23254L876). Trading on a split-adjusted basis commenced on July 7, 2025.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of maintaining Nasdaq listing compliance. The primary contingency addressed is the potential loss of listing status due to low share price, which the reverse split aims to resolve.
Investor Verification Checklist
- Verify the new CUSIP number (23254L876) with your brokerage to ensure proper account adjustment.
- Confirm the number of shares held post-split, noting the rounding rules for fractional entitlements.
- Check the adjusted strike prices and share counts for any outstanding options or warrants held.
- Monitor the stock price on July 7, 2025, to confirm the company meets Nasdaq bid price requirements.